MAPK3 and neoplasm: In the context of TT directed at the MEK/ERK1/2 axes, the reactivation of ERK1/2 may occur in tumor cells, despite the use of selective inhibitors, allowing for a rapid recovery of alternative or MAPK pathway signaling and subsequent treatment escape supporting proliferation and survival of the tumor.